Mikito Shimizu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mikito Shimizu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Goichi Beck
Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
1 shared publication Hideki Mochizuki
Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
1 shared publication- Hisae Sumi
Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
1 shared publication Keigo Kihara
Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
1 shared publicationMakoto Kinoshita
Department of Neurology, Neuroscience, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
1 shared publication- Masanori P. Takahashi
Clinical Neurophysiology, Department of Clinical Laboratory and Biomedical Sciences, The University of Osaka Graduate School of Medicine, Japan
1 shared publication
Latest Publications
- Open Access
- 24 September 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 20 (9) , 2589-2590
Disruption of neuronal actin barrier promotes the entry of disease-implicated proteins to exacerbate amyotrophic lateral sclerosis pathology
- 24 September 2024
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 20 (9) , 2589-2590
Open AccessDisruption of neuronal actin barrier promotes the entry of disease-implicated proteins to exacerbate amyotrophic lateral sclerosis pathology
- Open Access
- 24 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (47) , eadg3193
RGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.
- 24 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (47) , eadg3193
Open AccessRGMa collapses the neuronal actin barrier against disease-implicated protein and exacerbates ALS
Repulsive guidance molecule A (RGMa) was originally identified as a neuronal growth cone–collapsing factor. Previous reports have demonstrated the multifunctional roles of RGMa mediated by neogenin1. However, the pathogenic involvement of RGMa in amyotrophic lateral sclerosis (ALS) remains unclear. Here, we demonstrated that RGMa concentration was elevated in the cerebrospinal fluid of both patients with ALS and transgenic mice overexpressing the mutant human superoxide dismutase1 (mSOD1 mice). Treatment with humanized anti-RGMa monoclonal antibody ameliorated the clinical symptoms in mSOD1 mice. Histochemical analysis revealed that the anti-RGMa antibody significantly decreased mutant SOD1 protein accumulation in the motor neurons of mSOD1 mice via inhibition of actin depolymerization. In vitro analysis revealed that the anti-RGMa antibody inhibited the cellular uptake of the mutant SOD1 protein, presumably by reinforcing the neuronal actin barrier. Collectively, these data suggest that RGMa leads to the collapse of the neuronal actin barrier and promotes aberrant protein deposition, resulting in exacerbation of the ALS pathology.